亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A PHASE III TRIAL OF GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (GEMOX) VS RITUXIMAB PLUS GEMOX FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

医学 美罗华 弥漫性大B细胞淋巴瘤 吉西他滨 内科学 奥沙利铂 肿瘤科 淋巴瘤 临床研究阶段 胃肠病学 化疗 癌症 结直肠癌
作者
Mark Hertzberg,Matthew Ku,Olivier Catalani,Betsy Althaus,S Simko,Gareth P. Gregory
出处
期刊:Hematological Oncology [Wiley]
卷期号:39 (S2) 被引量:1
标识
DOI:10.1002/hon.165_2880
摘要

Introduction: Prognosis is poor for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), particularly those who are ineligible for autologous stem cell transplant (ASCT) or who relapse after second-line therapy (Gisselbrecht C, et al. Br J Haematol 2018). While chimeric antigen receptor therapies have shown favorable response rates in R/R DLBCL, convenient off-the-shelf options are needed, especially for patients with rapidly progressing disease (Sermer D, et al. Blood Adv 2020). Glofitamab is a full-length, humanized immunoglobulin G1 bispecific antibody with two regions that bind to CD20 (B cells) and one region that binds to CD3 (T cells). In an ongoing Phase I study in patients with R/R non-Hodgkin lymphoma, glofitamab monotherapy has induced high response rates with a manageable safety profile (NCT03075696; Hutchings M, et al. ASH 2020). Rituximab in combination with GemOx (R-GemOx) is widely used for patients with R/R DLBCL who are not eligible for ASCT (Mounier N, et al. Haematologica 2013). Methods: GO41944 (NCT04408638) is a Phase III, open-label, randomized trial designed to evaluate the safety and efficacy of glofitamab plus gemcitabine and oxaliplatin (glofit-GemOx) vs R-GemOx in patients with R/R DLBCL. Eligible patients must be aged ≥18 years, have histologically confirmed DLBCL (excluding transformed indolent disease, and high-grade B-cell lymphoma (BCL) with MYC and BCL2 and/or BCL6 rearrangements), and have received ≥1 prior systemic therapies; patients who have failed only one prior line of therapy must not be eligible for high-dose chemotherapy followed by ASCT. Prior treatment with GemOx, R-GemOx or a CD20xCD3 bispecific antibody is not permitted. Patients are randomized 2:1 to receive up to eight 21-day cycles of either glofit-GemOx (intravenous [IV], followed by up to four cycles of glofitamab monotherapy) or R-GemOx (IV). A single dose of obinutuzumab is administered seven days prior to the first glofitamab administration. Randomization is stratified by number of prior lines of therapy and outcome of last systemic therapy (relapsed vs refractory). The primary objective is overall survival from time of randomization. Secondary efficacy objectives include progression-free survival, complete and overall response rates, duration of response, and time to deterioration in physical functioning and fatigue, and in lymphoma symptoms. Safety objectives comprise rate of adverse events, change from baseline in targeted vital signs and clinical laboratory test results, and tolerability. Pharmacokinetic, immunogenicity and biomarker endpoints will also be explored. The study started on February 17, 2021; an estimated enrollment of 270 patients by the study completion date of March 2022 is anticipated. EA – previously submitted to ASCO and EHA 2021. The research was funded by: F. Hoffmann-La Roche Ltd/Genentech, Inc. Third-party medical writing assistance, under the direction of the authors, was provided by Katie Buxton, PhD, of Ashfield MedComms, an Ashfield Health company, and was funded by F. Hoffmann-La Roche Ltd/Genentech, Inc. Keywords: Aggressive B-cell non-Hodgkin lymphoma, Ongoing Trials Conflicts of interests pertinent to the abstract M. Hertzberg Consultant or advisory role: Takeda, Gilead, F. Hoffmann-La Roche Ltd, MSD Honoraria: F. Hoffmann-La Roche Ltd, Janssen, Takeda, Bristol-Myers Squibb Research funding: F. Hoffmann-La Roche Ltd, Janssen, GSK M. Ku Consultant or advisory role: F. Hoffmann-La Roche Ltd, Antengene Research funding: Karyopharm O. Catalani Employment or leadership position: F. Hoffmann-La Roche Ltd B. Althaus Employment or leadership position: Genentech, Inc. Stock ownership: F. Hoffmann-La Roche Ltd S. Simko Employment or leadership position: Genentech, Inc. Stock ownership: F. Hoffmann-La Roche Ltd G. P. Gregory Consultant or advisory role: F. Hoffmann-La Roche Ltd, Novartis/Sandoz, Janssen, Gilead Honoraria: F. Hoffmann-La Roche Ltd Research funding: F. Hoffmann-La Roche Ltd, BeiGene, MSD, AbbVie, Janssen Educational grants: F. Hoffmann-La Roche Ltd, Novartis Other remuneration: Speakers' bureau: F. Hoffmann-La Roche Ltd; Expert testimony: Janssen

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
纯情的阁发布了新的文献求助10
7秒前
35秒前
忧郁血茗完成签到,获得积分10
35秒前
48秒前
59秒前
丰富的雅绿完成签到,获得积分10
1分钟前
1分钟前
帅气寄风完成签到,获得积分10
1分钟前
1分钟前
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
bkagyin的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
顾矜的应助被纯情的阁采纳,获得30
1分钟前
1分钟前
刻苦绿蕊完成签到,获得积分10
1分钟前
agathahqs的应助被纯情的阁采纳,获得10
1分钟前
丘比特的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.4的应助被纯情的阁采纳,获得10
1分钟前
田様的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
1分钟前
agathahqs的应助被纯情的阁采纳,获得10
1分钟前
上官若男的应助被落润晓采纳,获得10
1分钟前
1分钟前
务实的香薇完成签到,获得积分10
1分钟前
2分钟前
2分钟前
缥缈的觅风完成签到 ,获得积分10
2分钟前
Eva小飞鱼发布了新的文献求助10
2分钟前
2分钟前
落润晓发布了新的文献求助10
2分钟前
2分钟前
2分钟前
情怀的应助被Spike采纳,获得10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158827
求助须知:如何正确求助?哪些是违规求助? 9554476
关于积分的说明 21719316
捐赠科研通 7748395
什么是DOI,文献DOI怎么找? 3427099
关于科研通互助平台的介绍 2552000
邀请新用户注册赠送积分活动 2471370